CN112584836A - 一种ar拮抗剂联合parp抑制剂在制备治疗前列腺癌的药物中的用途 - Google Patents

一种ar拮抗剂联合parp抑制剂在制备治疗前列腺癌的药物中的用途 Download PDF

Info

Publication number
CN112584836A
CN112584836A CN201980053699.9A CN201980053699A CN112584836A CN 112584836 A CN112584836 A CN 112584836A CN 201980053699 A CN201980053699 A CN 201980053699A CN 112584836 A CN112584836 A CN 112584836A
Authority
CN
China
Prior art keywords
prostate cancer
compound
formula
inhibitor
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980053699.9A
Other languages
English (en)
Inventor
金春雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN112584836A publication Critical patent/CN112584836A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种式I化合物所示的AR拮抗剂或其可药用盐联合多聚二磷酸腺苷核糖聚合酶抑制剂(PARP抑制剂)在制备治疗前列腺癌的药物中的用途，该联合治疗方案展现较优的疾病控制率和客观响应率。

Description

PCT国内申请，说明书已公开。

Claims (19)

  1. PCT国内申请，权利要求书已公开。
CN201980053699.9A 2018-10-22 2019-10-21 一种ar拮抗剂联合parp抑制剂在制备治疗前列腺癌的药物中的用途 Pending CN112584836A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811227906 2018-10-22
CN2018112279061 2018-10-22
PCT/CN2019/112214 WO2020083187A1 (zh) 2018-10-22 2019-10-21 一种ar拮抗剂联合parp抑制剂在制备治疗前列腺癌的药物中的用途

Publications (1)

Publication Number Publication Date
CN112584836A true CN112584836A (zh) 2021-03-30

Family

ID=70330399

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980053699.9A Pending CN112584836A (zh) 2018-10-22 2019-10-21 一种ar拮抗剂联合parp抑制剂在制备治疗前列腺癌的药物中的用途

Country Status (3)

Country Link
CN (1) CN112584836A (zh)
TW (1) TW202029961A (zh)
WO (1) WO2020083187A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023226940A1 (zh) * 2022-05-23 2023-11-30 正大天晴药业集团股份有限公司 吲哚并七元酰肟类似物的用途及其药物组合

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019427A1 (zh) * 2010-08-09 2012-02-16 上海恒瑞医药有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2014036897A1 (zh) * 2012-09-04 2014-03-13 上海恒瑞医药有限公司 咪唑啉类衍生物、其制备方法及其在医药上的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019427A1 (zh) * 2010-08-09 2012-02-16 上海恒瑞医药有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2014036897A1 (zh) * 2012-09-04 2014-03-13 上海恒瑞医药有限公司 咪唑啉类衍生物、其制备方法及其在医药上的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIKUN LI ET AL.: "《Androgen receptor inhibitor – induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer》", 《SCIENCE SIGNALING》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023226940A1 (zh) * 2022-05-23 2023-11-30 正大天晴药业集团股份有限公司 吲哚并七元酰肟类似物的用途及其药物组合

Also Published As

Publication number Publication date
WO2020083187A1 (zh) 2020-04-30
TW202029961A (zh) 2020-08-16

Similar Documents

Publication Publication Date Title
CN105705148B (zh) 使用普那布林和紫杉烷的组合的癌症疗法
JP5709354B2 (ja) ｍＴＯＲ阻害剤投与によるがん患者の治療
CN113768933B (zh) Parp抑制剂用于治疗化疗耐药的卵巢癌或乳腺癌的用途
EP2054061A2 (en) Combination therapy
CN112587666A (zh) 用于治疗癌症的pd-1/pd-l1相互作用的小分子抑制剂和抗pd-1抗体的组合
WO2016168451A1 (en) Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment
WO2019016928A1 (ja) がん細胞の代謝の特異性に基づく新規抗悪性腫瘍剤
CN111728974B (zh) 西奥罗尼用于小细胞肺癌的治疗
TWI295173B (zh)
CN112584836A (zh) 一种ar拮抗剂联合parp抑制剂在制备治疗前列腺癌的药物中的用途
WO2018099423A1 (zh) 一种vegfr抑制剂与parp抑制剂联合在制备治疗胃癌的药物中的用途
EA011573B1 (ru) Препарат, потенцирующий противоопухолевый эффект, противоопухолевый препарат и способ лечения рака
CN112121169A (zh) 用于治疗具有高间质压力的肿瘤受试者的癌症的小分子抑制剂
WO2008066783A2 (en) Therapeutic materials and methods
KR20170045751A (ko) 고령이나 말기의 암환자를 치료 또는 경감하기 위한 의약 조성물
KR20240046527A (ko) 암치료를 위한 신규 경구용 약학적 조성물
JP2012520319A (ja) 膵臓癌の治療
WO2021057764A1 (zh) Pd-1抗体联合紫杉类化合物在制备治疗三阴性乳腺癌的药物中的用途
WO2021002887A1 (en) Gut-targeted nlrp3 antagonists and their use in therapy
CN113769097A (zh) Egfr/her2抑制剂联合嘧啶类抗代谢药物的用途
CN110680919A (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗肿瘤的药物的用途
EP2755655A1 (en) Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients
WO2022058418A1 (en) New use of inhibitors of the notch signalling pathway
AU2008356312A1 (en) Antitumor agent, kit, and method for treating cancer
WO2007013696A1 (ja) ６’－アミジノ－２’－ナフチル４－グアニジノベンゾエート又はその塩を含んでなる抗腫瘍剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination